Antineoplaston Cancer Therapy

This policy addresses antineoplaston (AN) cancer therapy proposed for malignancies such as lymphoma, melanoma, myeloma, sarcoma, as adjunctive treatment to limit recurrent tumors or increase salvage surgery eligibility, and as adjunctive postoperative hepatic arterial infusion with 5‑fluorouracil for colorectal liver metastases. Because AN therapy is not FDA‑approved, is offered primarily at the Burzynski Research Institute, and lacks sufficient high‑quality evidence of benefit, it is considered experimental/investigational and is not covered except within controlled clinical trials or for uses supported by FDA labeling or nationally recognized authoritative references with dosing consistent with those sources and subject to the member’s benefit contract.

"Lymphoma"

Sign up to see full coverage criteria, indications, and limitations.